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Abstract
Obesity is a risk factor for Barrett’s oesophagus and oesophageal adenocarcinoma. Adipose tissue secretes the hormone leptin. 
Leptin is a growth factor for several cell types, including Barrett’s cells and oesophageal adenocarcinoma cells. Statins are 
associated with reduced rates of Barrett’s oesophagus and oesophageal cancer and exhibit anti-cancer effects in vitro. The 
mechanisms of these effects are not fully established. We have examined the effects of leptin and the lipid-soluble statin, 
atorvastatin, on signalling via monomeric GTP-binding proteins and Akt. Proliferation and apoptosis were assessed in OE33 
cells. Akt activity was quantified by cell-based ELISA and in vitro kinase assay. Specific small-molecule inhibitors and a 
dominant-negative construct were used to reduce Akt activity. Small GTPases were inhibited using transfection of dominant-
negative plasmids, prenylation inhibitors and pretreatment with atorvastatin. Leptin stimulated Akt activity and cell prolifera-
tion and inhibited camptothecin-induced apoptosis in an Akt-sensitive manner. Leptin induced phosphorylation of Bad and 
FOXO1 in an Akt-sensitive manner. Leptin activated Ras, Rac, RhoA and cdc42. Transfection of dominant-negative plasmids 
confirmed that leptin-induced Akt activation required Ras, RhoA cdc42 but not Rac. Atorvastatin inhibited leptin-induced 
activation of Ras, RhoA, cdc42 and Akt. Co-treatment with mevalonate prevented these effects of atorvastatin. The protein 
kinase Akt is essential to the growth-promoting and anti-apoptotic effects of leptin in oesophageal adenocarcinoma cells. Akt 
is activated via Ras-, Rho- and cdc42-dependant pathways. Atorvastatin reduces leptin-induced Akt activation by inhibit-
ing prenylation of small GTPases. This may explain the reduced incidence of oesophageal adenocarcinoma in statin-users.
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Abbreviations
BO  Barrett’s oesophagus
DN-Akt  Dominant-negative Akt
ELISA  Enzyme-linked immunoabsorbant assay




NF-kB  Nuclear factor kappa B
OAC  Oesophageal adenocarcinoma
Introduction
OAC is an important cause of mortality and morbidity. In 
the USA and Europe, incidence rates have increased by 
approximately 7-fold in the last 40 years [1]. Survival rates 
for established OAC are poor (5-year survival less than 20%) 
[2, 3]. In most cases, OAC is thought to develop from the 
precursor lesion, BO, which is a metaplastic phenotypic 
change in the oesophageal mucosa from squamous to glan-
dular-type. Subsequently, cancer develops along a dysplasia-
carcinoma sequence. The pathogenesis of BO and OAC is 
complex but the two most established modifiable risk factors 
for both are acid-reflux and obesity (particularly central obe-
sity) [4]. The interaction of these is complex. Several lines 
of evidence of have suggested that actions and interactions 
between acid and peptides secreted by adipose tissue, at the 
level of the oesophageal epithelium, may promote the devel-
opment of OAC in addition to the combination of effects of 
lifestyle and effects on the gastrooeosphageal junction [5–7].
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We have demonstrated previously that the hormone lep-
tin, produced by adipose tissue, has important effects in 
stimulating proliferation and inhibiting apoptosis in Bar-
rett’s epithelial cells [8, 9]. Levels of leptin rise in propor-
tion to adipose tissue mass [5]. Increased leptin levels are 
an independent risk factor for the development of both BO 
and progression along the dysplasia-carcinoma sequence 
[10, 11]. Functional leptin receptors are expressed on the 
mucosa of BO and cultured Barrett’s cell lines [5, 8, 9] 
Leptin is also secreted into the gastric lumen by gastric 
chief cells and theoretically Barrett’s mucosa is exposed 
to leptin from both the circulation and gastric refluxate 
[12, 13].
In experimental in vitro models, acid-reflux also stimu-
lates proliferation and inhibits apoptosis in malignant and 
non-malignant Barrett’s cell lines [14, 15]; the combined 
effects of acid and leptin are synergistic [16]. Leptin has also 
been shown to increase the resistance of oesophageal cancer 
to chemotherapy in vivo and in vitro [17]. The mechanisms 
of these effects are incompletely defined.
The serine-threonine protein kinase Akt (also known as 
protein kinase B) is important in many systems in controlling 
proliferation and apoptosis. We have previously reported that 
Akt activation increases in Barrett’s mucosa along the non-
dysplastic to low-grade dysplasia to high-grade dysplasia 
sequence. Akt is activated in oesophageal Barrett’s cells by 
acid-reflux [18] and by hormones such as gastrin and gly-
cine-extended gastrin as well as leptin [7, 8, 19, 20]. In colon 
cancer cells, leptin-induced Akt activation is essential to the 
anti-apoptotic and proliferative actions [21]. Previously stud-
ies have outlined some of the pathways downstream of Akt 
that mediate the anti-apoptotic effects in Barrett’s epithelial 
cells but there are much less data on the mechanisms that 
are involved in the upstream pathways leading to activation 
of Akt in this system [18, 22]. Membrane-bound small GTP-
binding proteins (GTPases) are important regulators of the 
signalling between cell-membrane receptors and intracel-
lular signals, including protein kinases such as Akt. These 
GTP-binding proteins of the Ras, Rho, Rac and cdc42 sub-
families have been implicated in a variety of cellular pro-
cesses including proliferation, cell-survival, invasion and 
inflammation [23]. Activation of the small GTP-binding 
proteins by both typical tyrosine kinase-linked growth factor 
receptors, including leptin [24, 25], and 7-transmembrane 
G-protein coupled receptors has been described [26–28]. 
Previously, Ras has been shown to mediate anti-apoptotic 
signalling in Barrett’s cells [29, 30], but the role of these 
GTP-binding proteins in OAC and Barrett’s mucosa have 
not been fully explored. We have also previously shown that 
statins (HMG-CoA reductase inhibitors) have anti-cancer 
effects in OAC cells in vitro [29] and are associated with a 
reduced incidence of OAC in epidemiological studies [31], 
and the mechanisms of these effects have not been fully 
described but may involve small GTPases.
Therefore, in this study, we have examined the hypothesis 
that GTP-binding proteins are involved in the regulation of 
Akt activation by leptin and that atorvastatin, a potent lipid-
soluble statin, interferes with pro-oncogenic leptin signalling 
at the level of membrane-bound GTPases.
Methods
Cell culture, proliferation and apoptosis
OE33 OAC cells were cultured as described previously 
[8, 32]. For proliferation experiments, cells were serum-
starved for 24 h before stimulation with recombinant 
human leptin (1nM) (Bachem, UK), and then proliferation 
was assessed using a BrdU incorporation assay as previ-
ously described [20]. Apoptosis was induced by exposing 
serum-free leptin-treated cells with camptothecin (Merck, 
UK), and apoptosis quantified with the ApoPercentage 
assay as described previously [19]. We have previously 
confirmed that these assays provide comparable data to 
that obtained by cell counting and the MTT assay [8, 9] 
and caspase-3 activity and quantification of intracellular 
nucleosomes [16, 19]. For inhibitor studies, the Akt inhibi-
tors, API-2 and GSK690693 (both 1 μm) [33, 34] (Tocris, 
Abingdon, UK), were added 60 min prior to leptin. Cells 
were treated with adenoviral vector containing DN-Akt 
(Vector Biolabs, Pennsylvania, USA) 24 h prior to stimula-
tion with leptin as described [26].
Akt activation and downstream activity
Serum-starved OE33 cells were stimulated with leptin, sub-
sequently phosphorylated and non-phosphorylated Akt, Bad 
and FOXO1 (Forkhead box O1) were quantified in formalin-
fixed cells using commercially-available cell-based ELISAs 
(Active Motif, Waterloo, Belgium) as described previously 
[18]. Akt activity was additionally measured using an 
in vitro kinase activity as described previously [20].
Assessment of the on involvement of small GTPases
OE33 cells were treated 24 h before leptin stimulation with 
expression plasmids containing DN-Ras, DN-cdc42, DN-
RhoA and DN-Rac1 (cDNA Resource Centre, Bloomsburg 
University, Pennsylvania, USA), using previously described 
methodology [19]. Where appropriate, the prenylation 
inhibitors FTI276 and GGTI298 (both 10 μM) (both Tocris, 
Abingdon, Oxford, UK) were added 24 h prior to leptin stim-
ulation [29]. In selected experiments, atorvastatin (0.1 μM) 
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(Tocris) and mevalonate (100 μm) (Sigma) were initially 
added 72 h prior to stimulation with leptin, with a medium 
change with fresh reagents added after 48 h.
Assessment of GTPase activity
Activity of Ras, cdc42, RhoA and Rac1,2,3 in leptin-
stimulated OE33 cell lysates was quantified using G-LISA 
colormetric assays, according to the manufacturer’s 
instructions (Cytoskeleton, Inc, Denver, CO, USA).
Results
Inhibition of Akt reduces leptin‑stimulated 
proliferation and evasion of apoptosis
Leptin stimulated proliferation of OE33 cells, and this 
was significantly blocked (>80%) by 2 separate Akt-spe-
cific inhibitors and transfection with a DN-Akt construct 
(Fig. 1a). Leptin also demonstrated a significant anti-apop-
totic effect. Leptin reduced camptothecin-induced apoptosis 
by 40%. Pretreatment with both Akt inhibitors and the DN-







































Fig. 1  Effect of Akt inhibitors on the pro-proliferative and anti-
apoptotic effects of leptin in OE33 cells. (a) Effects on prolifera-
tion. Serum-starved OE33 cells were pretreated where appropriate 
before stimulation with leptin (1 nM) with the Akt inhibitors API-2 
or GSK690693 (both 1  μM), 60  min before leptin or a dominant-
negative adenoviral construct (DN-Akt) 24  h pre-leptin. Cell prolif-
eration after 24 h was measured using a specific BrdU incorporation 
ELISA. Results are expressed as mean ± SEM, N = 4, *P < 0.01 vs 
control unstimulated, **P < 0.01 vs leptin-stimulated. (b) Effects on 
apoptosis. OE33 cells were cultured for 42 h in serum-free medium 
or supplemented with 1  nM leptin. Camptothecin 10  μM was then 
added and apoptosis after a further 6 h quantified with the Biocolor 
APOPercentage™ assay. Results expressed as mean ± SEM, N = 4, 













































Fig. 2  Effect of leptin on activation of Akt. Serum-starved OE33 
cells were stimulated with leptin 1  nM. Where indicated inhibitors 
(API-2 1  μm, GSK690693 1  μM) were added 60  min prior to lep-
tin or a dominant-negative Akt adenoviral construct (DN-Akt) added 
24 h prior to leptin. (a) Effect on Akt phosphorylation. After 5 min, 
cells were formalin-fixed and subsequently phosphorylated Akt and 
total Akt levels quantified in fixed cells using a specific cell-based 
ELISA. Results for each well were normalised for cell content using 
subsequent crystal violet staining. Results are expressed as the ratio 
of phosphorylated/total kinase relative to control-treated cells. (b) 
Effect on Akt activity. After 5 min, cells were lysed and Akt kinase 
activity quantified in Akt immunoprecipitates using a specific kinase 
(K-LISA) kit. Results are expressed as phosphorylating activity com-
pared to untreated controls. Results are expressed as mean ± SEM, 
N = 5, *P < 0.01 vs control untreated, **P < 0.01 vs leptin-treated
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Leptin‑stimulated Akt is enzymatically active 
and leads to downstream signalling
The activation of Akt by leptin was confirmed using 2 differ-
ent assays. Leptin-stimulated Akt activation was assessed by 
assay measuring Akt phosphorylation (increased by 187%) 
as well as by a specific kinase assay (increased by 215%). 
Pretreatment with Akt inhibitors or the DN-Akt effectively 
blocked Akt activation, with similar effects in both assays 
(Fig. 2). Total Akt levels were unaltered by leptin or small-
molecule inhibitors (data not shown), consistent with previ-
ously published data [7, 8, 16].
To confirm that leptin-stimulated Akt was functionally 
active, we further assessed downstream markers of Akt 
activity as read-outs. Leptin stimulation led to an increase 
in the phosphorylation of both Bad (increased by 150%) 
(Fig. 3a) and FOXO1 (increased by 87%) (Fig. 3a, b) and in 
both cases this was significantly reduced by the Akt inhibi-
tors and the DN-Akt construct.
Akt activation by leptin requires small GTP‑binding 
protein activity
The activation of protein kinases is controlled in many 
cases by small GTP-binding protein. We examined the 
role of the small GTP-binding proteins Ras, Rac, Rho and 
cdc42 in leptin-stimulated Akt activation. Transfection of 
OE33 cells with DN-mutants of the different GTPases had 












































Fig. 3  Effect Akt inhibitors on leptin-stimulated phosphorylation of 
Bad and FOXO1. Serum-starved OE33 cells were stimulated with 
leptin 1  nM. Where indicated inhibitors (API-2 1  μm, GSK690693 
1 μM) were added 60 min prior to leptin or a DN-Akt adenoviral con-
struct added 24  h prior to leptin. After 5 min, cells were formalin-
fixed and phosphorylated and non-phosphorylated proteins assessed 
by specific cell-based ELISAs. (a) Effect on Bad-phosphorylation, 
(b) Effect on FOXO1-phosphorylation. Results for each well were 
normalised for cell content using subsequent crystal violet staining. 
Results are expressed as the ratio of phosphorylated/total protein rela-
tive to control-treated cells. Results are expressed as mean ± SEM, 













































Fig. 4  Effect of inhibition of small GTP-binding proteins on leptin-
stimulated Akt activity. OE33 cells were transfected with expression 
plasmids containing DN-Ras, DN-RhoA, DN-Rac1 or DN-cdc42. 
After 24 h serum-starvation, cells were stimulated with 1 nM leptin. 
(a) Effect on Akt phosphorylation. After 5 min, cells were formalin-
fixed and subsequently phosphorylated Akt and total Akt levels quan-
tified in fixed cells using a specific cell-based ELISA. Results for 
each well were normalised for cell content using subsequent crystal 
violet staining. Results are expressed as the ratio of phosphorylated/
total kinase relative to control-treated cells. (b) Effect on Akt activ-
ity. After 5 min, cells were lysed and Akt kinase activity quantified in 
Akt immunoprecipitates using a specific kinase (K-LISA) kit. Results 
are expressed as phosphorylating activity compared to untreated 
controls. Results are expressed as mean ± SEM, N = 5, *P < 0.01 vs 
control untreated, **P < 0.05 vs leptin-treated, ***P < 0.01 vs leptin-
treated
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activation by >80%, DN-RhoA by 50–57% and DN-cdc42 
by about 25%. DN-Rac1 had no effect on Akt activation. A 
similar pattern of results was seen whether Akt was assessed 
with either a cell-based ELISA for phosphorylated protein 
(Fig. 4a) or in a kinase assay (Fig. 4b).
Small GTP-binding protein is active when localised to the 
cell membrane; this localisation requires post-translational 
modification by prenylation with the addition of a farnesyl 
group (to Ras) and geranylgeranyl groups to Rac, Rho and 
cdc42). Therefore, we performed further studies using spe-
cific inhibitors of farnesylation and geranylgeranylation. 
The farnesyl transferase inhibitor FTI276 reduced leptin-
stimulated Akt activation by 85% and the geranylgeranyl 
transferase inhibitor GGTI298 reduced Akt activation by 
approximately 75%. Statins reduce the ability to prenylate 
GTP-binding protein by reducing the availability of farnesyl 
and geranylgeranyl intermediates subsequent to the inhibi-












































Fig. 5  Effect of prenylation inhibitors on leptin-stimulated Akt 
activity. Serum-starved OE33 cells were stimulated with 1  nM lep-
tin. Either 24 h prior to leptin stimulation cells were treated with the 
farnesylation inhibitor FT276 (10  μM) or the geranylgeranylation 
inhibitor GGT298 (10 μM) or 72 h prior to stimulation treated with 
atorvastatin (0.1  μM) (ATV) with or without mevalonate (100  μM) 
(MEV). (a) Effect on Akt phosphorylation. After 5 min, leptin stimu-
lation cells were formalin-fixed and subsequently phosphorylated 
Akt and total Akt levels quantified in fixed cells using a specific cell-
based ELISA. Results for each well were normalised for cell con-
tent using subsequent crystal violet staining. Results are expressed 
as the ratio of phosphorylated/total kinase relative to control-treated 
cells. (b) Effect on Akt activity. After 5 min, leptin stimulation cells 
were lysed and Akt kinase activity quantified in Akt immunoprecipi-
tates using a specific kinase (K-LISA) kit. Results are expressed as 
phosphorylating activity compared to untreated controls. Results 
are expressed as mean ± SEM, N = 5, *P < 0.01 vs control untreated, 






























































































Fig. 6  Effect of prenylation inhibitors on small GTPase activity. 
Serum-starved OE33 cells were stimulated with 1 nM leptin. Either 
24 h prior to leptin stimulation cells were treated with the farnesyla-
tion inhibitor FT276 (10  mM) or the geranylgeranylation inhibitor 
GGT298 (10 mM) or 72 h prior to stimulation treated with atorvas-
tatin (0.1 mM) (ATV) with or without mevalonate (100 mM) (MEV). 
Three minutes after, leptin stimulation cells were harvested and the 
activity of small GTPase was assessed. (a) Ras activity. (b) Rho 
activity. (c) Rac activity and (d) cdc42 activity. Results are expressed 
as mean ± SEM, N = 4, *P < 0.01 vs control untreated, **P < 0.05 vs 
leptin-treated, *** P < 0.01 vs leptin-treated, †P < 0.05 vs atorvasta-
tin-treated
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with the lipid-soluble statin, atorvastatin, also inhibited Akt 
activation by 50%. Co-treatment with mevalonate prevented 
this inhibitory effect (Fig. 5).
Leptin stimulates small GTP‑binding protein activity
To confirm the involvement of small GTPase in leptin 
signalling, the activity of all 4 classes of GTPase was 
assessed using specific assays. Leptin stimulation potently 
increased the activity of Ras, Rac, Rho and cdc42 (Fig. 6). 
The farnesyltransfer inhibitor inhibited the activity of Ras, 
whilst the geranylgeranylation inhibitor reduced the acti-
vation of Rac, Rho and cdc42. Pretreatment with atorv-
astatin reduced leptin-stimulated activation of all classes 
of GTP-binding protein (by 54–76%) and co-treatment 
with mevalonate significantly ameliorated this effect in 
all cases.
Conclusions
In this study, we have demonstrated for the first time the 
essential requirement for the small GTPases Ras, Rho and 
cdc42 in leptin-induced Akt activation in oesophageal 
cancer cells. We have also shown that the lipid-soluble 
statin, atorvastatin, inhibits leptin-induced pro-oncogenic 
signalling by reducing signalling via these membrane-
linked GTPases.
We have confirmed that leptin exerts important pro-
proliferative and anti-apoptotic effects on OAC cells. We 
have demonstrated the essential role of the protein kinase 
Akt in this pathway. We confirmed increased leptin-stim-
ulated Akt activity using two separate methods. Similar 
effects were seen using 3 different methods of inhibit-
ing Akt. Although the two different small-molecule Akt 
inhibitors used have been reported to be Akt selective, 
most kinase inhibitors are not completely specific; hence, 
we performed confirmatory experiments using transfec-
tion with a dominant-negative adenoviral construct. All 
these results were consistent and clearly implicate Akt as 
a downstream mediator in the effects of leptin in oesopha-
geal cancer cells.
The specific downstream effectors of the Akt activity 
in this model remain to be clarified. Important actions of 
Akt include phosphorylation of Forkhead (FOXO) tran-
scription factors, which leads to subsequent sequestration 
in the cytosol and inhibition of transcriptional activity 
and phosphorylation and reduced activity of the proap-
optotic protein Bad. These have been implicated in the 
anti-apoptotic effect mechanisms of other signalling sys-
tems, such as that induced by gastrin [36]. We used these 
two markers primarily as read-outs to confirm the func-
tional activity of Akt in OE33 cells. Our results confirm 
the functional enzymatic activity of Akt in the system, 
although, at present, we cannot definitely implicate either 
Bad or FOXO1 as downstream mediators of Akt. FOXO1 
is known to be an essential downstream mediator of the 
central anorectic effects of activation of the leptin recep-
tor [37]. Other downstream targets of Akt, such as the 
NF-κB pathway and stabilisation of COX-2 mRNA, are 
likely to be important in the anti-apoptotic effects of Akt 
in Barrett’s oesophageal cells [19, 20]. Recent studies have 
also further highlighted the potential central role of Akt 
in Barrett’s oesophageal cancer progression: signalling 
via the insulin/insulin-like growth factor-1 axis and HER2 
receptor also activates Akt along the Barrett’s dysplasia-
cancer sequence [38]. This latter study did not examine the 
upstream activators of Akt or the downstream effectors.
Our results show that activation of the leptin receptor 
activates small GTP-binding proteins of all 4 subfami-
lies studied (Ras, Rho, Rac and cdc42). The data from 
the dominant-negative transfection studies clearly dem-
onstrated that although leptin-induced Akt activation was 
independent of Rac activation, there was a requirement for 
all three other GTP-binding protein families. Inhibition 
of Ras had by far the greatest inhibitory effect on leptin-
induced Akt activity, and there were smaller effects from 
inhibiting RhoA and cdc42. These data show that leptin-
induced Akt activation involves Ras, Rho and cdc42. 
There did not seem to be an absolute requirement for any 
specific GTP-binding protein, although Ras seemed to 
have the dominant role in signalling. Previously, leptin 
has been shown to activate all of Ras, Rho, Rac and cdc42 
in a variety cell models, although the exact significance of 
these changes and the downstream effectors have not been 
fully described. In colon cancer cells, leptin activates Rho, 
Rac and cdc42 which are involved in enhancing migration 
and invasion [24, 39]. There are a wealth of data examin-
ing downstream signalling from the leptin receptor, this is 
concentrated on protein kinases and transcription factors 
and there are relatively few studies examining the specific 
role of the small GTPase families [40].
We further explored different pharmacological methods 
to manipulate GTP-binding protein signalling and the effects 
on Akt activation. The results with the prenylation inhibi-
tors were consistent with the dominant-negative plasmids. 
Ras is predominantly farnesylated, whilst Rho, Rac and 
cdc42 are geranylgeranylated [35]. The addition of the lipid 
tails allows localisation of the GTP-binding protein to the 
inner side of the cell membrane, where they are functionally 
involved in signalling from many receptors. The farnesyl 
transferase inhibitor reduced Akt activation more than the 
geranylgeranyl transferase inhibitor, in keeping both with the 
dominant role of Ras in leptin-induced Akt activation, and 
the subsidiary but important roles of Rho and cdc42.
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Previous studies, both from our own group and others, 
have shown that statins have anti-proliferative and proapop-
totic actions in oesophageal adenocarcinoma cells [29, 41, 
42]. Clinical epidemiological studies have shown associa-
tions between statin use and reduced incidences of both BO 
and OAC [43–46] and improved overall and cancer-specific 
survival after surgery for OAC [47], suggesting that these 
effects of statins do have clinical correlations. However, the 
exact mechanism(s) underlying these apparent protective 
associations are not fully defined [5], but the clinical and 
experimental data do support further the further exploration 
of statins as chemopreventative agents in BO.
Statins inhibit the essential early step in the pathway for 
the formation of mevalonate. Mevalonate is the precursor to 
cholesterol but also the precursor to farnesyl pyrophosphate 
and geranylgeranyl pyrophosphate, which are the required 
substrates for the prenylation and membrane localisation 
of small GTP-binding proteins. We pretreated OE33 cells 
with the lipid-soluble statin atorvastatin at approximately 
the same concentration as can be found with high-dose clini-
cal use (40–80 mg daily) [48, 49]. Atorvastatin significantly 
reduced by Akt activation and GTP-binding protein activ-
ity. These effects of atorvastatin were abolished by adding 
back mevalonate. Mevalonate is downstream of HMG-CoA 
reductase in the biosynthetic pathways and is the precursor 
farnesyl and geranylgeranyl pyrophosphate, suggesting that 
the effects of atorvastatin were mediated by the reduction in 
the availability of intermediates for prenylation and resultant 
reduction in GTP-binding protein signalling.
Although potentially useful anti-cancer effects of statins 
in vitro against oesophageal cancer cells and non-malignant 
Barrett’s oesophageal cells have been documented, consist-
ent with the clinical observations, some of these studies 
have been criticised for using what were clearly supraphysi-
ological statin concentrations [50]. In this current study, 
we specifically used atorvastatin concentrations that can be 
achieved with standard dosing regimens [48, 49]. The inhibi-
tory effects of atorvastatin demonstrated in this study were 
clearly less than those obtained with the more specific exper-
imental tools to inhibit Akt and small GTP-binding proteins 
(such as the dominant-negative constructs and prenylation 
inhibitors). This presumably reflects the less than total inhi-
bition of the mevalonate pathway possible with pharmaco-
logically feasible statin levels: even then this atorvastatin 
concentration is well over the  IC50 for HMG-CoA-reductase 
(15.2 nM [51]. Higher degrees of apoptosis and inhibition of 
proliferation have been achieved using considerably higher 
concentrations of statins (up to 50 μm) [41, 42]. The  speci-
ficity of the pharmacological effects and clinical relevance 
of these effects are open to question.
Recently, alternative methods of inhibition of small 
GTPase signalling by statins have been described: atorvas-
tatin and pitavastatin inhibited Rac signalling by enhancing 
degradation of Rac in a prenylation-independent manner 
[52]. In our current study, the effects of atorvastatin were 
reversed by mevalonate favouring a prenylation-dependant 
pathway.
The effects of statins in potentially preventing the devel-
opment or progression of OAC in vivo are undoubtedly com-
plex, but our current data suggest that direct effects at the 
level of the oesophageal epithelial cells may be involved. 
Although the experimental cell-line studies implicating 
leptin signalling, GTPases and the ameliorating effect of 
statins [29, 53] are all consistent with the epidemiological 
and clinical studies [43, 54–56], these particular pathways 
have not been examined as yet in the animal models of Bar-
rett’s carcinogenesis [57].
Similarly, the mechanisms linking obesity and the devel-
opment of OAC are complex. Direct effects of adipose tis-
sue mediators such as leptin are but one of the likely factors 
including lifestyle, environment and disruption of the anti-
reflux barrier [5, 6]. However, our studies further confirm 
that leptin can have important pro-neoplastic effects directly 
on the oesophageal glandular epithelium. The protein kinase 
Akt has an essential role in these leptin-mediated effects 
and the small GTP-binding proteins Ras, Rho and cdc42 are 
involved in regulation Akt activity. Further studies examin-
ing the pharmacological modulation of Akt in oesophageal 
neoplasia and pre-neoplasia are warranted. Statins, in this 
case atorvastatin, by affecting GTP-binding protein pre-
nylation and activation can reduce Akt activation and the 
potential role of statins to prevent OAC should be explored 
further.
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